« Back to Record
Aftimos, P., Rolfo, C., Rottey, S., Barthélémy, P., Borg, C., Park, K., Oh, D. Y., Kim, S. W., De Jonge, N., Hanssens, V., Zwanenpoel, K., Molthoff, C., Vugts, D., Dreier, T., Verheesen, P., van Dongen, G. A. M. S., Jacobs, J., Van Rompaey, L., Hultberg, A., Michieli, P., Pauwels, P., Fung, S., Thibault, A., De Haard, H., Leupin, N., & Awada, A. (2021). The nhance® mutation-equipped anti-met antibody argx-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients. Biomedicines, 9(6), 665. doi:10.3390/biomedicines9060665
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/328621



